192 related articles for article (PubMed ID: 23958433)
1. Clinical significance of NUCB2 mRNA expression in prostate cancer.
Zhang H; Qi C; Li L; Luo F; Xu Y
J Exp Clin Cancer Res; 2013 Aug; 32(1):56. PubMed ID: 23958433
[TBL] [Abstract][Full Text] [Related]
2. High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer.
Zhang H; Qi C; Wang A; Li L; Xu Y
Tumour Biol; 2014 Mar; 35(3):2025-8. PubMed ID: 24092574
[TBL] [Abstract][Full Text] [Related]
3. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.
Zhang H; Qi C; Wang A; Yao B; Li L; Wang Y; Xu Y
J Exp Clin Cancer Res; 2013 Oct; 32(1):77. PubMed ID: 24422979
[TBL] [Abstract][Full Text] [Related]
4. Nucleobindin 2 expression is an independent prognostic factor for clear cell renal cell carcinoma.
Qi C; Ma H; Zhang HT; Gao JD; Xu Y
Histopathology; 2015 Apr; 66(5):650-7. PubMed ID: 25322808
[TBL] [Abstract][Full Text] [Related]
5. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
8. High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients.
Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Wang Z; Xie H; Dai B; Xu J; Ye D
Oncotarget; 2017 May; 8(21):35244-35254. PubMed ID: 27806328
[TBL] [Abstract][Full Text] [Related]
9. High expression of nucleobindin 2 is associated with poor prognosis in gastric cancer.
Altan B; Kaira K; Okada S; Saito T; Yamada E; Bao H; Bao P; Takahashi K; Yokobori T; Tetsunari O; Nishiyama M; Yamada M
Tumour Biol; 2017 Jul; 39(7):1010428317703817. PubMed ID: 28714371
[TBL] [Abstract][Full Text] [Related]
10. Increased nucleobindin-2 (NUCB2) transcriptional activity links the regulation of insulin sensitivity in Type 2 diabetes mellitus.
Guo Y; Liao Y; Fang G; Dong J; Li Z
J Endocrinol Invest; 2013 Nov; 36(10):883-8. PubMed ID: 23765387
[TBL] [Abstract][Full Text] [Related]
11. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
12. Nucleobindin 2 expression is an independent prognostic factor for bladder cancer.
Cho JM; Moon KT; Lee HJ; Shin SC; Choi JD; Kang JY; Yoo TK
Medicine (Baltimore); 2020 Mar; 99(13):e19597. PubMed ID: 32221080
[TBL] [Abstract][Full Text] [Related]
13. Nucleobindin 2 in human breast carcinoma as a potent prognostic factor.
Suzuki S; Takagi K; Miki Y; Onodera Y; Akahira J; Ebata A; Ishida T; Watanabe M; Sasano H; Suzuki T
Cancer Sci; 2012 Jan; 103(1):136-43. PubMed ID: 21988594
[TBL] [Abstract][Full Text] [Related]
14. Expression of RABEX-5 and its clinical significance in prostate cancer.
Zhang H; Cheng S; Wang A; Ma H; Yao B; Qi C; Liu R; Qi S; Xu Y
J Exp Clin Cancer Res; 2014 Apr; 33(1):31. PubMed ID: 24716822
[TBL] [Abstract][Full Text] [Related]
15. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.
Zhang H; Wei Q; Liu R; Qi S; Liang P; Qi C; Wang A; Sheng B; Li L; Xu Y
PLoS One; 2014; 9(3):e91069. PubMed ID: 24651764
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the adaptation to ER stress by KLF4 facilitates melanoma cell metastasis via upregulating NUCB2 expression.
Zhang D; Lin J; Chao Y; Zhang L; Jin L; Li N; He R; Ma B; Zhao W; Han C
J Exp Clin Cancer Res; 2018 Jul; 37(1):176. PubMed ID: 30055641
[TBL] [Abstract][Full Text] [Related]
18. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
19. Expression of SOCSs in human prostate cancer and their association in prognosis.
Zhu JG; Dai QS; Han ZD; He HC; Mo RJ; Chen G; Chen YF; Wu YD; Yang SB; Jiang FN; Chen WH; Sun ZL; Zhong WD
Mol Cell Biochem; 2013 Sep; 381(1-2):51-9. PubMed ID: 23666742
[TBL] [Abstract][Full Text] [Related]
20. mTOR-dependent modulation of gastric nesfatin-1/NUCB2.
Li Z; Xu G; Li Y; Zhao J; Mulholland MW; Zhang W
Cell Physiol Biochem; 2012; 29(3-4):493-500. PubMed ID: 22508056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
